Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Pia Fondazione Di Culto E Religione Card G Panico

Research site

Italy Via Pio X 4, 73039 Tricase, Italy

  • 47 trials recruiting
  • Colorectal cancer metastatic · Dementia Alzheimer's type · Hepatocellular carcinoma
  • Adults and children

About Specializations

Pia Fondazione Di Culto E Religione Card G Panico in Tricase, Italy specialises in clinical trials of conditions such as Colorectal cancer metastatic, Dementia Alzheimer's type, Hepatocellular carcinoma, Colorectal cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Alzheimer's Disease and Cognitive Impairment

The medical center is at the forefront of research in Alzheimer's Disease and related cognitive impairments. The focus is on understanding the progression and potential therapeutic interventions for Mild Cognitive Impairment due to Alzheimer's Disease and Alzheimer's Disease Dementia.

  • Clinical Dementia Rating-Sum of Boxes (CDR-SB) assessments
  • Safety and tolerability of novel treatments

Through innovative clinical trials, the center aims to improve the quality of life for patients by exploring new treatment avenues and enhancing existing therapeutic strategies.

Colorectal Cancer

Specializing in colorectal cancer, the center conducts cutting-edge research on molecularly selected and resectable primary colorectal cancer. The UNICORN study exemplifies the center's commitment to advancing preoperative targeted treatments.

  • Pathological complete response (pCR) and major response (pMR) rates
  • Short-course preoperative targeted treatments

By focusing on personalized medicine, the center seeks to enhance surgical outcomes and long-term survival rates for colorectal cancer patients.

Diffuse Large B-Cell Lymphoma (DLBCL)

The center is a leader in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Research efforts are directed towards evaluating novel combination therapies to improve patient outcomes.

  • Progression-free survival (PFS) comparisons
  • CD30-positive population studies

Through rigorous clinical trials, the center aims to provide new hope for patients with challenging lymphoma cases by optimizing therapeutic regimens.

Hepatocellular Carcinoma (HCC)

In the realm of hepatocellular carcinoma (HCC), the center is pioneering research on advanced treatment combinations. The focus is on improving survival outcomes for patients with untreated locally advanced or metastatic HCC.

  • Investigator-assessed progression-free survival (PFS) and overall survival (OS)
  • Combination therapies involving atezolizumab, bevacizumab, and tiragolumab

By exploring innovative therapeutic combinations, the center strives to set new standards in the management of liver cancer.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Pio X 473039 TricaseItaly
Open in maps ↗
Recruiting now
47 trials
Conditions studied
55

More sites in TricaseItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

89 clinical trials

Agitation+1

Recruiting

A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dextromethorphan Hydrobromide

Dementia Alzheimer's type

Recruiting

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Oesophageal squamous cell carcinoma

Recruiting

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Colorectal cancer metastatic

Recruiting

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Chronic lymphocytic leukaemia+2

Recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Dementia of the Alzheimer's type with delusions

Recruiting

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fesoterodine
  • Sponsor:Maplight Therapeutics Inc.

Colorectal cancer metastatic

Recruiting

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.